PL1811979T3 - Mikrokapsułki zawierające metyloksantynę i kortykosteroid - Google Patents
Mikrokapsułki zawierające metyloksantynę i kortykosteroidInfo
- Publication number
- PL1811979T3 PL1811979T3 PL05786942T PL05786942T PL1811979T3 PL 1811979 T3 PL1811979 T3 PL 1811979T3 PL 05786942 T PL05786942 T PL 05786942T PL 05786942 T PL05786942 T PL 05786942T PL 1811979 T3 PL1811979 T3 PL 1811979T3
- Authority
- PL
- Poland
- Prior art keywords
- minicapsules
- delivery system
- self
- methylxanthine
- corticosteroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61278604P | 2004-09-27 | 2004-09-27 | |
US61278404P | 2004-09-27 | 2004-09-27 | |
US61278504P | 2004-09-27 | 2004-09-27 | |
PCT/IE2005/000106 WO2006035418A2 (en) | 2004-09-27 | 2005-09-27 | Microcapsules comprising a methylxanthine and a corticosteroid |
EP05786942A EP1811979B1 (en) | 2004-09-27 | 2005-09-27 | Microcapsules comprising a methylxanthine and a corticosteroid |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1811979T3 true PL1811979T3 (pl) | 2009-04-30 |
Family
ID=35636768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05786942T PL1811979T3 (pl) | 2004-09-27 | 2005-09-27 | Mikrokapsułki zawierające metyloksantynę i kortykosteroid |
Country Status (8)
Country | Link |
---|---|
US (4) | US20070292523A1 (pl) |
EP (7) | EP2444071A1 (pl) |
AT (1) | ATE413165T1 (pl) |
CA (3) | CA2581764A1 (pl) |
DE (1) | DE602005010899D1 (pl) |
ES (1) | ES2401185T3 (pl) |
PL (1) | PL1811979T3 (pl) |
WO (3) | WO2006035418A2 (pl) |
Families Citing this family (216)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US7655252B2 (en) | 1999-04-28 | 2010-02-02 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US20030060494A1 (en) * | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
PL373780A1 (pl) * | 2002-02-25 | 2005-09-19 | Diffusion Pharmaceuticals Llc | Sole bipolarnych trans-karotenoidów i ich zastosowania |
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
PT1492511E (pt) | 2002-04-09 | 2009-04-09 | Flamel Tech Sa | Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s) |
WO2003084517A2 (fr) * | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules d’amoxicilline |
US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
CA2553690C (en) * | 2004-01-22 | 2016-05-24 | Sung Lan Hsia | Topical co-enzyme q10 formulations and methods of use |
PL1811979T3 (pl) * | 2004-09-27 | 2009-04-30 | Sigmoid Pharma Ltd | Mikrokapsułki zawierające metyloksantynę i kortykosteroid |
DK1836665T3 (da) | 2004-11-19 | 2013-04-15 | Glaxosmithkline Llc | Fremgangsmåde til specialtilpasset afgivelse af medikamentkombinationsprodukter med variabel dosis til individualisering af terapier |
FR2889810A1 (fr) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
EP1853544A4 (en) | 2005-02-24 | 2010-06-16 | Diffusion Pharmaceuticals Llc | TRANSCAROTENOIDS AND THEIR SYNTHESIS, THEIR PREPARATION AND USES THEREOF |
EP1865967A4 (en) * | 2005-04-08 | 2011-02-09 | Chimerix Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES |
US8642577B2 (en) * | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
US20080249186A1 (en) * | 2005-10-14 | 2008-10-09 | Givaudan Sa | Fungicidal Composition |
WO2007047539A2 (en) * | 2005-10-14 | 2007-04-26 | Medtronic, Inc. | Localized delivery to the lymphatic system |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8685478B2 (en) | 2005-11-21 | 2014-04-01 | Philip Morris Usa Inc. | Flavor pouch |
US9023400B2 (en) * | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
WO2007148340A2 (en) * | 2006-06-22 | 2007-12-27 | Mirik Medical Ltd. | Adverse drug reaction reduction |
WO2008023869A1 (en) | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
KR20090065519A (ko) * | 2006-08-30 | 2009-06-22 | 자고텍 아게 | 니솔디핀을 포함하는 방출 제어형 고형 경구 투여 제제 |
WO2008068778A2 (en) * | 2006-12-05 | 2008-06-12 | Alembic Limited | Extended release pharmaceutical composition of pramipexole |
HUE046465T2 (hu) * | 2006-12-22 | 2020-03-30 | Ironwood Pharmaceuticals Inc | Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére |
US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
EP2380564B1 (en) | 2007-04-04 | 2014-10-22 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
AU2008246305B2 (en) | 2007-04-13 | 2013-03-21 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
EP2061587A1 (en) | 2007-04-26 | 2009-05-27 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
US20100215737A1 (en) * | 2007-05-01 | 2010-08-26 | Ivan Coulter | Combination pharmaceutical compositions |
EP2152304B1 (en) | 2007-05-02 | 2018-08-22 | The Regents of the University of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US7541384B2 (en) | 2007-06-08 | 2009-06-02 | Axcan Pharma Inc. | Mesalamine suppository |
US8436051B2 (en) | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
US8217083B2 (en) * | 2007-06-08 | 2012-07-10 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
WO2009008006A2 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
KR100869444B1 (ko) * | 2007-07-11 | 2008-11-18 | 주식회사 중외제약 | 유비데카레논을 함유하는 다층정 비타민 복합제제 |
WO2009010884A2 (en) | 2007-07-16 | 2009-01-22 | Philip Morris Products S.A. | Tobacco-free oral flavor delivery pouch product |
US8124147B2 (en) * | 2007-07-16 | 2012-02-28 | Philip Morris Usa Inc. | Oral pouch products with immobilized flavorant particles |
US8206751B2 (en) * | 2007-10-31 | 2012-06-26 | Diffusion Pharmaceuticals Llc | Class of therapeutics that enhance small molecule diffusion |
US20090123390A1 (en) | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Compositions for the treatment of gastrointestinal inflammation |
GB2458403B (en) | 2007-11-13 | 2010-01-13 | Meritage Pharma Inc | Stabilised corticosteroid compositions |
US8993542B2 (en) * | 2008-01-25 | 2015-03-31 | Chimerix Inc. | Methods of treating viral infections |
US8729070B2 (en) * | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
EP2254420A4 (en) * | 2008-02-20 | 2012-02-15 | Targia Pharmaceuticals | CNS PHARMACEUTICALS AND METHOD FOR THEIR USE |
EP2265612B1 (en) | 2008-02-29 | 2017-04-05 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
BRPI0909030A2 (pt) * | 2008-03-05 | 2018-03-13 | Panacea Biotec Ltd | composições farmacêuticas de liberação modificada compreendendo micofenolato e processos para as mesmas. |
RU2571857C2 (ru) | 2008-03-18 | 2015-12-20 | Ново Нордиск А/С | Стабилизированные по отношению к протеазам ацилированные аналоги инсулина |
KR20100136997A (ko) | 2008-04-11 | 2010-12-29 | 싸이토테크 랩스, 엘엘씨 | 암세포에서 아폽토시스를 유도하는 방법 및 용도 |
WO2009134962A2 (en) * | 2008-04-30 | 2009-11-05 | The Regents Of The University Of California | Claudin-4 binding peptides, compositions and methods of use |
WO2009158625A2 (en) * | 2008-06-26 | 2009-12-30 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders |
EP2315571A4 (en) * | 2008-07-16 | 2013-05-01 | Surmodics Pharmaceuticals Inc | METHOD FOR PRODUCING MICROPARTICLES WITH BIOACTIVE PEPTIDES |
IT1393244B1 (it) * | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
WO2010017328A2 (en) * | 2008-08-06 | 2010-02-11 | Rgo Biosciences Llc | Cyclodextrin conjugates |
JP5924834B2 (ja) | 2008-09-02 | 2016-05-25 | アマリン ファーマシューティカルズ アイルランド リミテッド | エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法 |
IE20090793A1 (en) * | 2008-10-13 | 2010-06-23 | Sigmoid Pharma Ltd | A delivery system |
US20100124560A1 (en) * | 2008-11-14 | 2010-05-20 | Mcneil Ab | Multi portion intra-oral dosage form and use thereof |
EP2370059A1 (en) * | 2008-11-28 | 2011-10-05 | Novo Nordisk A/S | Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides |
WO2010065489A1 (en) * | 2008-12-02 | 2010-06-10 | Sciele Pharma, Inc. | Alpha2-adrenergic agonist and angiotensin ii receptor antagonist composition |
SG173612A1 (en) | 2009-02-10 | 2011-09-29 | Amarin Pharma Inc | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
EP2400840A4 (en) * | 2009-02-24 | 2012-08-01 | Madeira Therapeutics | LIQUID STATINE FORMULATIONS |
US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
RU2624506C2 (ru) | 2009-04-29 | 2017-07-04 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения |
CN102458109B (zh) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
AU2010247750B2 (en) | 2009-05-11 | 2016-09-22 | Berg Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
GB2483815B (en) | 2009-05-18 | 2013-12-25 | Sigmoid Pharma Ltd | Composition comprising oil drops |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
SG176571A1 (en) * | 2009-05-19 | 2012-01-30 | Vivia Biotech Sl | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
PT2443246T (pt) | 2009-06-15 | 2018-03-14 | Amarin Pharmaceuticals Ie Ltd | Composições e métodos para reduzir os triglicéridos sem aumentar os níveis de ldl-c num indivíduo em terapia de estatinas concomitante |
EP2445339B1 (en) * | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Diffusion enhancing compound and its use with a thrombolytic |
US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
US8470304B2 (en) | 2009-08-04 | 2013-06-25 | Avidas Pharmaceuticals Llc | Therapeutic vitamin D sun-protecting formulations and methods for their use |
EP2464341B1 (en) * | 2009-08-12 | 2022-07-06 | Sublimity Therapeutics Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
WO2011032916A1 (de) * | 2009-09-17 | 2011-03-24 | Basf Se | Mit wirkstoffhaltigen überzügen beschichtete pellets |
BR122019016628B8 (pt) | 2009-09-23 | 2021-07-27 | Amarin Corp Plc | uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular |
US8747562B2 (en) * | 2009-10-09 | 2014-06-10 | Philip Morris Usa Inc. | Tobacco-free pouched product containing flavor beads providing immediate and long lasting flavor release |
US20120263784A1 (en) * | 2009-10-12 | 2012-10-18 | Lyka Labs Limited | Emergency contraceptive |
US20130072458A1 (en) * | 2009-10-30 | 2013-03-21 | Chimerix, Inc. | Methods of Treating Viral Associated Diseases |
AU2010321533A1 (en) * | 2009-11-23 | 2012-05-31 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
EP2534150B1 (en) | 2010-02-12 | 2017-04-05 | Chimerix, Inc. | Methods of treating viral infection |
AU2011248620B2 (en) | 2010-04-26 | 2015-11-26 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
ES2654945T3 (es) * | 2010-06-02 | 2018-02-15 | Diffusion Pharmaceuticals Llc | Formulaciones orales de carotenoides trans bipolares |
CA2706272C (en) * | 2010-06-03 | 2020-05-05 | Accucaps Industries Limited | Multi phase soft gel capsules, apparatus and method thereof |
US20120003312A1 (en) * | 2010-06-30 | 2012-01-05 | Aptapharma, Inc. | Multilayer Minitablets with Different Release Rates |
KR20130101515A (ko) * | 2010-08-23 | 2013-09-13 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. | 위에 활성제를 전달하기 위한 조성물 |
GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
ES2386177B1 (es) * | 2010-09-21 | 2013-09-23 | Lipotec, S.A. | Nanocapsulas conteniendo microemulsiones |
GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
IT1405998B1 (it) * | 2010-12-09 | 2014-02-06 | Bionest Ltd | Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato |
BR112013018397A2 (pt) * | 2011-01-18 | 2016-10-11 | Equine Nutriceuticals Llc | suplemento equino nutricional |
JP6092844B2 (ja) | 2011-04-04 | 2017-03-08 | バーグ エルエルシー | 中枢神経系腫瘍の治療方法 |
US9433583B2 (en) | 2011-04-22 | 2016-09-06 | Frank J. Farrell | Colon vitamin |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
JP6322575B2 (ja) * | 2011-06-29 | 2018-05-09 | アビダス・フアーマシユーテイカルズ・エル・エル・シー | 脂質マイクロカプセルのデリバリービヒクルを含む局所用製剤およびその使用 |
US20140296263A1 (en) | 2011-07-19 | 2014-10-02 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
US9101547B2 (en) * | 2011-08-04 | 2015-08-11 | Nano And Advanced Materials Institute Limited | Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery |
US9320744B2 (en) | 2011-10-19 | 2016-04-26 | Dhea Llc | DHEA bioadhesive controlled release gel |
GB201118182D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to organic compounds |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
CN102423483A (zh) * | 2011-11-24 | 2012-04-25 | 西北农林科技大学 | 一种复方雷米普利纳米乳抗高血压药物 |
ITUD20110196A1 (it) * | 2011-12-02 | 2013-06-03 | Asoltech S R L | Composizione a base di ubidecarenone |
JP6307442B2 (ja) | 2012-01-06 | 2018-04-04 | アマリン ファーマシューティカルス アイルランド リミテッド | 対象の高感度(hs−crp)のレベルを低下させる組成物および方法 |
CN103211788B (zh) * | 2012-01-18 | 2017-07-18 | 北京天衡药物研究院有限公司 | 硝苯地平膜控缓释微丸胶囊 |
US10588857B2 (en) * | 2012-03-29 | 2020-03-17 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
MX2014012096A (es) | 2012-04-11 | 2014-11-21 | Novo Nordisk As | Formulaciones de insulina. |
CN104364255A (zh) | 2012-04-13 | 2015-02-18 | 康塞特医药品有限公司 | 取代的黄嘌呤衍生物 |
RS61288B1 (sr) * | 2012-06-15 | 2021-02-26 | Conaris Res Institute Ag | Farmaceutska kompozicija koja sadrži nikotinsku kiselinu i/ili nikotinamid i/ili triptofan za pozitivan uticaj na crevnu mikrobiotu |
KR20150036252A (ko) | 2012-06-29 | 2015-04-07 | 애머린 파마슈티칼스 아일랜드 리미티드 | 스타틴 요법 중인 대상체에서 심혈관 사건의 위험을 감소시키는 방법 |
GB201212010D0 (en) * | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
GB201304662D0 (en) * | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
WO2014135965A1 (en) * | 2013-03-07 | 2014-09-12 | Capsugel Belgium Nv | Bismuth liquid filled hard capsules |
CN110075130A (zh) | 2013-03-14 | 2019-08-02 | 塞拉拜姆有限责任公司 | 益生生物和/或治疗剂的靶向胃肠道递送 |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US8652516B1 (en) * | 2013-03-15 | 2014-02-18 | Cerovene, Inc. | Doxycycline formulations, and methods of treating rosacea |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US20140294795A1 (en) * | 2013-03-28 | 2014-10-02 | Houn Simon Hsia | Nutritional Composition |
US9592264B2 (en) | 2013-04-05 | 2017-03-14 | U.S. Nutraceuticals, LLC | Delivery system for saw palmetto extract and carotenoid |
SG11201508272YA (en) | 2013-04-08 | 2015-11-27 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
EA034143B1 (ru) | 2013-09-04 | 2020-01-09 | Берг Ллк | Способы лечения рака непрерывной инфузией кофермента q10 |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
EP3057604B1 (en) | 2013-10-14 | 2021-06-09 | Nanosphere Health Sciences Inc. | Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers |
CN103565751A (zh) * | 2013-10-17 | 2014-02-12 | 广州帝奇医药技术有限公司 | 一种长效缓释微丸及其制备方法 |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
US10272036B2 (en) | 2013-12-06 | 2019-04-30 | Intervet Inc. | Composition for oral delivery of bioactive agents |
PL3079675T3 (pl) | 2013-12-13 | 2020-07-27 | Conaris Research Institute Ag | Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid do zastosowania w korzystnym wpływaniu na poziom lipidów we krwi poprzez modyfikowanie mikrobioty jelitowej |
AU2014363430A1 (en) | 2013-12-13 | 2016-06-16 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
US9095607B2 (en) * | 2013-12-31 | 2015-08-04 | Antonino Cavallaro | Gel for topical application of clove essential oil with broad spectrum anti-inflammatory action and method of preparing same |
CN103767070B (zh) * | 2014-01-15 | 2015-08-05 | 中国烟草总公司广东省公司 | 角鲨烯与虾青素组合物液态前体脂质体的制备方法及其降基减害应用 |
WO2015120201A1 (en) * | 2014-02-05 | 2015-08-13 | Kashiv Pharma, Llc | Abuse-resistant drug formulations with built-in overdose protection |
WO2015130760A1 (en) * | 2014-02-25 | 2015-09-03 | Orbis Biosciences, Inc. | Taste masking drug formulations |
CN103859588B (zh) * | 2014-03-20 | 2016-04-13 | 广西中烟工业有限责任公司 | 角鲨烯与虾青素组合物多囊脂质体的制备及其降基减害 |
CA2944004C (en) | 2014-03-27 | 2023-08-15 | Roland W. Winterfield | Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy |
US20170216296A1 (en) | 2014-04-18 | 2017-08-03 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
CN105294791A (zh) * | 2014-06-10 | 2016-02-03 | 无锡康福特药物科技有限公司 | 一种大环内酯类药物的超微粉体及其制备方法 |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
DK3157508T3 (da) * | 2014-06-19 | 2021-02-15 | Solural Pharma ApS | Fast oral doseringsform af lipofile forbindelser |
MX2017000384A (es) * | 2014-07-09 | 2017-04-27 | Sun Pharmaceutical Ind Ltd | Forma de dosificacion en capsulas de succinato de metoprolol. |
US9700530B2 (en) * | 2014-07-09 | 2017-07-11 | Sun Pharmaceutical Industries Limited | Capsule dosage form of metoprolol succinate |
EP3197436B1 (en) * | 2014-09-24 | 2022-03-09 | Vital Beverages Global Inc. | Compositions and methods for selective gi tract delivery |
DK3200828T3 (da) | 2014-10-03 | 2020-10-12 | Lachesis Biosciences Ltd | Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser |
US9468659B2 (en) | 2014-11-06 | 2016-10-18 | NWO Stem Cure, LLC | Nutraceutical supplement with Lactobacillus rhamnosus |
US9980993B2 (en) | 2014-11-06 | 2018-05-29 | NWO Stem Cure, LLC | Nutraceutical supplement with Lactobacillus rhamnosus |
PT3215127T (pt) | 2014-11-07 | 2021-02-10 | Sublimity Therapeutics Ltd | Composições que compreendem ciclosporina |
US11707436B2 (en) | 2014-12-15 | 2023-07-25 | Nanosphere Health Sciences Inc. | Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of NSAIDS |
WO2016105498A1 (en) | 2014-12-23 | 2016-06-30 | Synthetic Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US10028919B2 (en) | 2015-03-10 | 2018-07-24 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
CN107735170A (zh) * | 2015-04-02 | 2018-02-23 | 南洋理工大学 | 聚合物‑脂质共混物形成的管状和囊泡结构及其形成方法 |
GB201509606D0 (en) * | 2015-06-03 | 2015-07-15 | Anabio Technologies Ltd | Microencapsulates containing stabilised marine-derived oil, and methods for production thereof |
JPWO2017022248A1 (ja) * | 2015-08-04 | 2018-05-24 | 富士カプセル株式会社 | 腸溶性カプセル |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US20170119680A1 (en) * | 2015-10-30 | 2017-05-04 | R.P. Scherer Technologies, Llc | Extended release film-coated capsules |
WO2017134524A2 (en) * | 2016-02-01 | 2017-08-10 | I2O Pharma Ltd. | Spherical microcapsules with enhanced oral bioavailability |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
CN109152839A (zh) | 2016-03-24 | 2019-01-04 | 扩散药品有限公司 | 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途 |
CN109937025B (zh) | 2016-04-20 | 2022-07-29 | 多斯医学公司 | 生物可吸收眼部药物的递送装置 |
US10092615B2 (en) * | 2016-04-30 | 2018-10-09 | Fairhaven Health, Llc | Nutritional supplements for improving male fertility |
US10137111B2 (en) | 2016-08-11 | 2018-11-27 | Adamis Pharmaceuticals Corporation | Drug compositions comprising an anti-parasitic and proton pump inhibitor |
HRP20221324T1 (hr) | 2016-12-16 | 2022-12-23 | Novo Nordisk A/S | Farmaceutski pripravci koji sadrže inzulin |
WO2018170319A1 (en) * | 2017-03-17 | 2018-09-20 | Vitalis Llc | Compositions and methods for treating multiple sclerosis |
US10214704B2 (en) | 2017-04-06 | 2019-02-26 | Baker Hughes, A Ge Company, Llc | Anti-degradation and self-healing lubricating oil |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
AU2018313766A1 (en) | 2017-08-07 | 2020-02-20 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
CA3071798A1 (en) * | 2017-09-12 | 2019-03-21 | Eth Zurich | Transmembrane ph-gradient polymersomes for the quantification of ammonia in body fluids |
MX2020005632A (es) * | 2017-12-01 | 2020-09-03 | Cable Components Group Llc | Composiciones espumables y metodos para fabricar articulos espumosos. |
EP3720844A4 (en) | 2017-12-08 | 2021-08-11 | Adamis Pharmaceuticals Corporation | MEDICINAL COMPOSITIONS |
US11338020B2 (en) | 2018-01-09 | 2022-05-24 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
US20210038654A1 (en) * | 2018-03-16 | 2021-02-11 | Persephone Biosciences | Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same |
WO2019183209A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
TWI657825B (zh) * | 2018-04-04 | 2019-05-01 | 美進醫藥公司 | 治療心血管疾病的組合藥物及其製備和使用方法 |
US20210121432A1 (en) * | 2018-04-17 | 2021-04-29 | Université De Caen Normandie | Bambuterol for the Treatment of Alzheimer's Disease |
US11266615B2 (en) | 2018-06-08 | 2022-03-08 | Harrow Ip, Llc | Pyrimethamine-based pharmaceutical compositions and methods for fabricating thereof |
KR20210018229A (ko) * | 2018-06-08 | 2021-02-17 | 해로우 아이피, 엘엘씨 | 피리메타민-기초된 제약학적 조성물 및 이들을 가공하기 위한 방법 |
SG11202102872QA (en) | 2018-09-24 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of cardiovascular events in a subject |
SG11202106144VA (en) | 2018-12-11 | 2021-07-29 | Disruption Labs Inc | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
CN110025611A (zh) * | 2019-03-14 | 2019-07-19 | 吉林大学 | 一种槲皮素对酪氨酸磷酸酶1b抑制中的应用 |
US20210023023A1 (en) * | 2019-07-25 | 2021-01-28 | Vasayo, Llc | Liposomal nutraceutical compositions and methods of making the same |
CN114650833A (zh) | 2019-09-13 | 2022-06-21 | 芬奇治疗控股有限责任公司 | 用于治疗孤独症谱群障碍的组合物和方法 |
EP4045630A1 (en) | 2019-10-18 | 2022-08-24 | Finch Therapeutics Holdings LLC | Compositions and methods for delivering a bacterial metabolite to a subject |
WO2021097288A1 (en) | 2019-11-15 | 2021-05-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating neurodegenerative diseases |
CN110951801B (zh) * | 2019-11-25 | 2021-04-13 | 北京工商大学 | 聚氧乙烯月桂醚在莫纳可林k生产中的应用 |
WO2021142347A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for non-alcoholic steatohepatitis (nash) |
WO2021142353A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv) |
WO2021142358A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatic encephalopathy (he) |
WO2021144625A1 (en) * | 2020-01-18 | 2021-07-22 | Maneesh Pharmaceuticals Ltd | The oral synergistic composition and its process for the preparation |
US20210275531A1 (en) * | 2020-03-04 | 2021-09-09 | VK Research Associates Inc | Phosphodiesterase-5 inhibitor combinations, methods of making, and methods of use thereof |
WO2021202806A1 (en) | 2020-03-31 | 2021-10-07 | Finch Therapeutics Holdings Llc | Compositions comprising non-viable fecal microbiota and methods of use thereof |
US20210318587A1 (en) * | 2020-04-13 | 2021-10-14 | Massachusetts Institute Of Technology | Melanin-peptide-based photonic materials |
JP2023522210A (ja) * | 2020-04-16 | 2023-05-29 | ザ メディカル カレッジ オブ ウィスコンシン インク | 気道逆流の治療のためのhivプロテアーゼ阻害剤のエアロゾル化製剤 |
WO2021239614A1 (en) * | 2020-05-25 | 2021-12-02 | Metaceutic Aps | Nutraceutical composition |
WO2021247601A1 (en) * | 2020-06-02 | 2021-12-09 | Model Medicines, Inc. | Methods and compositions for treating rna viral infections |
WO2022178294A1 (en) | 2021-02-19 | 2022-08-25 | Finch Therapeutics Holdings Llc | Compositions and methods for providing secondary bile acids to a subject |
WO2022204757A1 (en) * | 2021-03-30 | 2022-10-06 | Noxopharm Limited | Improved isoflavone formulation |
CN113244197B (zh) * | 2021-05-24 | 2023-02-28 | 天方药业有限公司 | 一种卡马西平缓释胶囊剂及其制备方法 |
US20230191047A1 (en) * | 2021-12-17 | 2023-06-22 | Belhaven BioPharma Inc. | Medical counter measures including dry powder formulations and associated methods |
WO2023187831A1 (en) * | 2022-03-30 | 2023-10-05 | Amrita Vishwa Vidyapeetham | A nano in micro formulation and process thereof |
WO2023215279A1 (en) * | 2022-05-03 | 2023-11-09 | Nocion Therapeutics, Inc. | Compositions and methods for treatment of inflammatory bowel disease |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2907460A1 (de) * | 1978-03-07 | 1979-09-13 | Sandoz Ag | Neue resorbierbare galenische kompositionen |
US4279632A (en) * | 1979-05-08 | 1981-07-21 | Nasa | Method and apparatus for producing concentric hollow spheres |
IT1148784B (it) * | 1980-04-09 | 1986-12-03 | Eurand Spa | Procedimento per la preparazione di microcapsule in un veicolo liquido |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
DE3224619A1 (de) * | 1981-07-14 | 1983-05-19 | Freund Industrial Co., Ltd., Tokyo | Orale pharmazeutische zusammensetzung |
US4481157A (en) * | 1982-04-27 | 1984-11-06 | Morishita Jintan Co., Ltd. | Method and apparatus for production of microcapsules |
US4597959A (en) * | 1982-04-30 | 1986-07-01 | Arthur Barr | Sustained release breath freshener, mouth and palate coolant wafer composition and method of use |
JPS5953410A (ja) * | 1982-09-20 | 1984-03-28 | Fujisawa Pharmaceut Co Ltd | 新型ソフトカプセル剤 |
US4422985A (en) * | 1982-09-24 | 1983-12-27 | Morishita Jintan Co., Ltd. | Method and apparatus for encapsulation of a liquid or meltable solid material |
JPS59131355A (ja) * | 1983-01-17 | 1984-07-28 | 森下仁丹株式会社 | 多重軟カプセルの製法 |
HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
DE3331009A1 (de) * | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4601894A (en) * | 1985-03-29 | 1986-07-22 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
US4565161A (en) * | 1985-04-08 | 1986-01-21 | Uraken Canada Limited | Steam generation |
US4749574A (en) * | 1986-04-14 | 1988-06-07 | Fujisawa Pharmaceutical Co., Ltd. | Sustained-release transdermal delivery preparations |
US4749454A (en) * | 1986-11-17 | 1988-06-07 | Solarex Corporation | Method of removing electrical shorts and shunts from a thin-film semiconductor device |
US4857335A (en) * | 1987-03-27 | 1989-08-15 | Lim Technology Laboratories, Inc. | Liquid controlled release formulations and method of producing same via multiple emulsion process |
ATE109970T1 (de) * | 1987-09-03 | 1994-09-15 | Univ Georgia Res Found | Cyclosporin-augenmittel. |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
JP2806564B2 (ja) * | 1989-07-20 | 1998-09-30 | 森下仁丹株式会社 | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
US5260071A (en) * | 1989-12-18 | 1993-11-09 | Lemelson Jerome H | Drug units and methods for using same |
DK0465238T3 (da) * | 1990-07-04 | 1994-05-02 | Shionogi & Co | Fremgangsmåde til fremstilling af ikke-kohæsive overtræk |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5418010A (en) * | 1990-10-05 | 1995-05-23 | Griffith Laboratories Worldwide, Inc. | Microencapsulation process |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
JP3313124B2 (ja) * | 1991-07-31 | 2002-08-12 | 森下仁丹株式会社 | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
DE4201179A1 (de) * | 1992-01-17 | 1993-07-22 | Alfatec Pharma Gmbh | Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung |
US5571533A (en) * | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
AU3941493A (en) * | 1992-03-30 | 1993-11-08 | Alza Corporation | Viscous suspensions of controlled-release drug particles |
EP0573978B1 (en) * | 1992-06-12 | 1999-04-21 | Kao Corporation | Bath additive composition comprising surfactant-containing seamless capsules and method for producing the capsules. |
JP3405746B2 (ja) | 1992-10-28 | 2003-05-12 | フロイント産業株式会社 | シームレスカプセルの製造方法 |
GB9300875D0 (en) * | 1993-01-18 | 1993-03-10 | Ucb Sa | Nanocapsule containing pharmaceutical compositions |
US5843347A (en) * | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
FR2707184B1 (fr) * | 1993-07-08 | 1995-08-11 | Rhone Poulenc Nutrition Animal | Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique. |
US5562909A (en) * | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
DE4332041C2 (de) * | 1993-09-21 | 1997-12-11 | Rentschler Arzneimittel | Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FR2721510B1 (fr) * | 1994-06-22 | 1996-07-26 | Rhone Poulenc Rorer Sa | Nanoparticules filtrables dans des conditions stériles. |
US5650232A (en) * | 1994-10-07 | 1997-07-22 | Warner-Lambert Company | Method for making seamless capsules |
FR2725623A1 (fr) * | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5827531A (en) * | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5529783A (en) * | 1994-12-19 | 1996-06-25 | Mcneil-Ppc, Inc. | Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan |
KR0167613B1 (ko) * | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 조성물 |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5674495A (en) * | 1995-02-27 | 1997-10-07 | Purdue Research Foundation | Alginate-based vaccine compositions |
US5595757A (en) * | 1995-03-29 | 1997-01-21 | Warner-Lambert Company | Seamless capsules |
US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
DE19549852B4 (de) * | 1995-11-29 | 2009-06-04 | Novartis Ag | Cyclosporin enthaltende Präparate |
JP3759986B2 (ja) * | 1995-12-07 | 2006-03-29 | フロイント産業株式会社 | シームレスカプセルおよびその製造方法 |
US5686133A (en) * | 1996-01-31 | 1997-11-11 | Port Systems, L.L.C. | Water soluble pharmaceutical coating and method for producing coated pharmaceuticals |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
CA2288876A1 (en) * | 1997-05-06 | 1998-11-12 | Xiao Yu Wu | Drug delivery system |
JP4102459B2 (ja) * | 1997-05-14 | 2008-06-18 | 森下仁丹株式会社 | 生体高分子を合成するシームレスカプセルおよびその製造方法 |
SE9702533D0 (sv) * | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
JP3090198B2 (ja) * | 1997-08-21 | 2000-09-18 | 日本電気株式会社 | 半導体装置の構造およびその製造方法 |
DE69825173T2 (de) * | 1997-10-30 | 2005-08-25 | Morishita Jintan Co. Ltd. | Doppelschichtige kapsel von ungesättigten fettsäuren oder deren derivate und verfahren zu deren herstellung |
IT1296585B1 (it) * | 1997-11-28 | 1999-07-14 | Uni Di Pavia | Microcapsule contenenti materiale seminale per l'inseminazione strumentale nella specie suina |
US6509346B2 (en) * | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US20040062802A1 (en) * | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
US6174466B1 (en) * | 1998-05-08 | 2001-01-16 | Warner-Lambert Company | Methods for making seamless capsules |
JPH11322587A (ja) * | 1998-05-18 | 1999-11-24 | Sumitomo Chem Co Ltd | 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物 |
KR100336090B1 (ko) * | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
JP3039863B1 (ja) * | 1998-12-25 | 2000-05-08 | 不二精工株式会社 | ロッキングプレス装置 |
US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
AU4428000A (en) * | 1999-05-14 | 2000-12-05 | Coraltis Ltd. | Pulse-delivery oral compositions |
WO2000074720A1 (fr) * | 1999-06-09 | 2000-12-14 | Mochida Pharmaceutical Co., Ltd. | Systeme de liberation dans les voies digestives inferieures |
US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DK1280521T3 (da) * | 2000-05-12 | 2005-08-08 | Pharmacia & Upjohn Co Llc | Vaccinesammensætning, fremgangsmåde til fremstilling deraf og fremgangsmåde til vaccination af hvirveldyr |
US20040258702A1 (en) * | 2000-06-22 | 2004-12-23 | Blonder Joan P. | Vaccine delivery |
GB0018527D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Composition |
US6565888B1 (en) * | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
FI20002215A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
US6585997B2 (en) * | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US6951655B2 (en) * | 2001-10-11 | 2005-10-04 | Imi Biomed, Inc. | Pro-micelle pharmaceutical compositions |
US20040126428A1 (en) * | 2001-11-02 | 2004-07-01 | Lyn Hughes | Pharmaceutical formulation including a resinate and an aversive agent |
US6974592B2 (en) * | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
JP4226846B2 (ja) * | 2002-06-07 | 2009-02-18 | キャタレント・ジャパン株式会社 | 口腔内で崩壊可能なソフトカプセル剤 |
US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
CA2520660C (en) * | 2003-03-28 | 2013-08-20 | Sigmoid Biotechnologies Limited | Solid oral dosage form containing seamless microcapsules |
RU2541809C2 (ru) * | 2003-04-04 | 2015-02-20 | Зоетис Пи ЛЛК | Микрофлюидизированные эмульсии "масло в воде" и композиции вакцины |
US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
TW201240679A (en) * | 2004-03-12 | 2012-10-16 | Capsugel Belgium Nv | Pharmaceutical formulations |
GB0417481D0 (en) * | 2004-08-05 | 2004-09-08 | Etiologics Ltd | Combination therapy |
PL1811979T3 (pl) * | 2004-09-27 | 2009-04-30 | Sigmoid Pharma Ltd | Mikrokapsułki zawierające metyloksantynę i kortykosteroid |
CN101212953A (zh) * | 2005-03-29 | 2008-07-02 | 麦克内尔-Ppc股份有限公司 | 具有疏水介质中的亲水药物的组合物 |
US7842312B2 (en) * | 2005-12-29 | 2010-11-30 | Cordis Corporation | Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
US20080124279A1 (en) * | 2006-11-17 | 2008-05-29 | Antoine Andremont | Colonic delivery using Zn/pectin beads with a Eudragit coating |
US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
-
2005
- 2005-09-27 PL PL05786942T patent/PL1811979T3/pl unknown
- 2005-09-27 EP EP11175018A patent/EP2444071A1/en not_active Withdrawn
- 2005-09-27 WO PCT/IE2005/000106 patent/WO2006035418A2/en active Application Filing
- 2005-09-27 US US11/663,836 patent/US20070292523A1/en not_active Abandoned
- 2005-09-27 EP EP05786872A patent/EP1814530A2/en not_active Ceased
- 2005-09-27 CA CA002581764A patent/CA2581764A1/en not_active Abandoned
- 2005-09-27 DE DE602005010899T patent/DE602005010899D1/de active Active
- 2005-09-27 EP EP05786892A patent/EP1802287A2/en not_active Withdrawn
- 2005-09-27 WO PCT/IE2005/000104 patent/WO2006035416A2/en active Application Filing
- 2005-09-27 CA CA002581816A patent/CA2581816A1/en not_active Abandoned
- 2005-09-27 ES ES10183934T patent/ES2401185T3/es active Active
- 2005-09-27 EP EP08019218A patent/EP2156826A1/en not_active Withdrawn
- 2005-09-27 EP EP05786942A patent/EP1811979B1/en active Active
- 2005-09-27 EP EP08019217A patent/EP2153824A1/en not_active Withdrawn
- 2005-09-27 US US11/663,834 patent/US20080113031A1/en not_active Abandoned
- 2005-09-27 EP EP10183934A patent/EP2322146B1/en not_active Not-in-force
- 2005-09-27 AT AT05786942T patent/ATE413165T1/de not_active IP Right Cessation
- 2005-09-27 US US11/663,832 patent/US20080020018A1/en not_active Abandoned
- 2005-09-27 WO PCT/IE2005/000105 patent/WO2006035417A2/en active Application Filing
- 2005-09-27 CA CA002581775A patent/CA2581775A1/en not_active Abandoned
-
2014
- 2014-04-23 US US14/260,084 patent/US20140234410A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2156826A1 (en) | 2010-02-24 |
EP2322146A3 (en) | 2011-06-15 |
ES2401185T3 (es) | 2013-04-17 |
EP2322146B1 (en) | 2012-12-12 |
CA2581775A1 (en) | 2006-04-06 |
EP1814530A2 (en) | 2007-08-08 |
EP2444071A1 (en) | 2012-04-25 |
US20080113031A1 (en) | 2008-05-15 |
US20080020018A1 (en) | 2008-01-24 |
EP1802287A2 (en) | 2007-07-04 |
US20070292523A1 (en) | 2007-12-20 |
EP2322146A2 (en) | 2011-05-18 |
WO2006035418A3 (en) | 2006-08-31 |
CA2581764A1 (en) | 2006-04-06 |
ATE413165T1 (de) | 2008-11-15 |
EP1811979B1 (en) | 2008-11-05 |
US20140234410A1 (en) | 2014-08-21 |
WO2006035417A2 (en) | 2006-04-06 |
CA2581816A1 (en) | 2006-04-06 |
WO2006035416A2 (en) | 2006-04-06 |
WO2006035417A3 (en) | 2006-08-31 |
WO2006035416A3 (en) | 2007-03-15 |
EP2153824A1 (en) | 2010-02-17 |
EP1811979A2 (en) | 2007-08-01 |
WO2006035418A2 (en) | 2006-04-06 |
DE602005010899D1 (de) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1811979T3 (pl) | Mikrokapsułki zawierające metyloksantynę i kortykosteroid | |
WO2001091728A3 (en) | Nanoemulsion formulations | |
HK1098960A1 (en) | Method and composition for treating rhinitis | |
WO2004056337A3 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
ATE309798T1 (de) | Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate | |
MX338355B (es) | Sistemas de suministro de farmaco topico para uso oftalmico. | |
TW200744665A (en) | Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof | |
WO2009086112A3 (en) | Apparatus and methods for delivering therapeutic agents | |
RS52367B (en) | GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES | |
WO2007111720A3 (en) | Formulation of insoluble small molecule therapeutics in lipid-based carriers | |
WO2006060325A3 (en) | Coated drug delivery formulations | |
WO2004066983A3 (en) | Controlled release of highly soluble agents | |
WO2004017943A3 (en) | Non-vesicular cationic lipid formulations | |
CA2585754C (en) | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy | |
WO2011089619A3 (en) | Method and balloon catheter assembly for treating bifurcation lesions | |
AR025343A1 (es) | Un sistema de suministro farmaceutico para vitamina c y vitamina e y uso de una combinacion de ambas para la preparacion de una droga para tratar oprevenir estados que involucran estres oxidante | |
AU5487101A (en) | Cosmetic or dermatological product comprising a freeze-dried hydrocolloid composition | |
GB2434363B (en) | Amphiphilic nanotubes and micelles comprising them for use in the delivery of biologically active agents | |
WO2008071965A8 (en) | Aqueous mica suspension | |
Badawi et al. | Improvement of the microbiological activity of topical ketoconazole using microemulsion systems | |
AU2003244885A1 (en) | Oral delivery of biological active agents in a nanoemulsion formulation to the human body | |
Mitsou | Development of microemulsions for the administration of bioactive compounds | |
AR084298A1 (es) | Comprimido farmaceutico orodispersable a base de zolpidem | |
UA93411C2 (ru) | Композиции, которые содержат витамин, и их применение для получения обогащенных кормовых продуктов и композиций для личной гигиены | |
Bourmenskaya | A study of individual differences by means of stage-by-stage formation of mental actions and notions |